GLUEHealthcare · BiotechnologyThe 10 Wall Street analysts covering Monte Rosa Therapeutics, Inc. hold a median 12-month price target of $27 — +150.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Monte Rosa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on GLUE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +150.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | UBS | Assumes | Buy | $17 → $19 |
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 1 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | $25 |
| 1 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 9 Sept 2026 | Wedbush | Reiterates | Outperform | — |
| 9 Sept 2026 | Wedbush | Reiterates | Outperform | $27 |
| 25 Aug 2026 | Guggenheim | Reiterates | Buy | $28 |
| 25 Aug 2026 | Guggenheim | Reiterates | Buy | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $35 → $28 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | $31 → $27 |
| 7 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $29 → $27 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 3 Aug 2026 | Wedbush | Maintains | Outperform | $37 → $27 |
| 3 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 30 June 2026 | Guggenheim | Maintains | Buy | — |
| 30 June 2026 | Guggenheim | Maintains | Buy | $30 → $35 |
| 11 May 2026 | JP Morgan | Maintains | Overweight | — |
| 18 Mar 2026 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
GLUE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Monte Rosa Therapeutics, Inc. returned −17.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 14% of US stocks
Cheaper than 6% of US stocks
Cheaper than 45% of US stocks
Cheaper than 73% of US stocks
Higher than 4% of US stocks
Higher than 8% of US stocks
Higher than 7% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Monte Rosa Therapeutics, Inc. has a market value of $918.0M and an enterprise value of $334.9M.
Revenue in the twelve months to 30 June 2026: $28.7M. The latest quarter shrank 61.3% year on year.
Net income over the same four quarters: −$161.1M, a −560.9% net margin.
Diluted earnings per share, trailing twelve months: $−2.18.
Free cash flow in the twelve months to 30 June 2026: −$32.1M.
Trailing P/E: 49.2×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Monte Rosa Therapeutics, Inc. employs 173 people — $166K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Monte Rosa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Monte Rosa Therapeutics lacks the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report.
Why it matters — GLUE watchers may note the article's caution about the company's prospects for an earnings beat before the Q3 release.
Monte Rosa Therapeutics announced a milestone achievement associated with initiating a second Phase 2 clinical study of its VAV1-directed molecular glue degrader MRT-6160 (DDY391).
Why it matters — The announcement marks another Phase 2 study initiation for a GLUE drug candidate.
Monte Rosa Therapeutics reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The four-week dosing study showed sustained NEK7 degradation, reductions in inflammatory and atherogenic biomarkers, and a safety profile comparable with placebo.
Why it matters — The results suggest MRT-8102 is hitting its biological targets with an encouraging safety profile, marking a meaningful clinical milestone for the company's lead pipeline candidate.
Monte Rosa Therapeutics granted inducement equity awards to five newly hired non-executive employees, including non-qualified stock options to purchase 86,725 shares at an exercise price of $11.26 and restricted stock units covering 19,150 shares, both subject to performance-based vesting schedules tied to continued employment.
Why it matters — GLUE watchers would care because the inducement grants signal hiring and incentive activity in the company's workforce, offered under Nasdaq Rule 5635(c)(4).
Monte Rosa Therapeutics discussed results from its GFORCE-1 Phase I trial of MRT-8102, a NEK7 molecular glue degrader being studied in cardiovascular disease risk, in a transcript published on Seeking Alpha. The item covers the company's presentation of these Phase I data for the candidate.
Why it matters — These Phase I results provide an early read on MRT-8102, a key pipeline candidate targeting cardiovascular disease risk, and offer GLUE watchers insight into the program's clinical progress.
The 10 Wall Street analysts covering Monte Rosa Therapeutics, Inc. have a median 12-month price target of $27, with estimates ranging from $19 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Monte Rosa Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Monte Rosa Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Monte Rosa Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +150.9% from the last close, and Ticker Nerd's factor model ranks Monte Rosa Therapeutics, Inc. 65 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Monte Rosa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $37 over the next 12 months.
Monte Rosa Therapeutics, Inc. returned -17.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release". Zacks Investment Research says Monte Rosa Therapeutics lacks the combination of two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins. Its current pipeline includes orally available small-molecule candidates for oncology, autoimmune and inflammatory disorders, and other serious diseases, using the body’s natural protein-degradation machinery to address targets that are difficult to treat with conventional drugs. The company’s research is centered on precision medicine approaches that combine chemistry, structural biology, proteomics, and computational methods to identify and optimize novel therapies. Monte Rosa Therapeutics, Inc. operates in the biotechnology sector, where targeted protein degradation is an important area of drug discovery and development.
CEO Dr. Markus Warmuth M.D. · 173 employees · United States · https://www.monterosatx.com
